Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Recruiting now

Conditions studied: Lymphoid Leukemia

In brief

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.

Key facts

Study ID
NCT05865301
Run by
Stanford University
People needed
500
Starts
2023-06-29
Expected to finish
2038-12-31
Last updated by the study team
2026-06-04

Who can join

Age: any, up to 26. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.